ArticleJournal of thoracic disease2025
The relationship between blood biomarkers and prognosis of pathologic stage IA pure-solid non-small cell lung cancer patients.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Association between the systemic inflammation response index and prognosis in lung cancer: a systematic review and meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: For patients with clinical stage IA (cIA) non-small cell lung cancer (NSCLC) who received the standard treatment of lobectomy combined with systematic lymph node dissection, some still might experience postoperative recurrence or metastasis. Previous studies have shown that lung cancer patients whose tumors appear as solid nodules on imaging have a higher recurrence rate compared to those with ground glass nodules. Thus, it would be recommended for postoperatively upstaged patients to receive additional adjuvant therapy. So far, there have not been reliable biomarkers to distinguish the subgroup of NSCLC patients with a higher risk of recurrence within the pathologic stage IA (pIA). Therefore, we aimed to investigate the prognostic role of preoperative blood biomarkers in patients with pIA pure-solid NSCLC undergoing surgery. Methods: We retrospectively reviewed clinical data of pIA NSCLC patients who underwent radical surgery between 2014 and 2016. For subgroup comparisons, we also collected information from NSCLC patients with pathological stage T1N1-2M0 (pT1N1-2M0) during the same period. The optimal cut-off value of biomarkers was determined by receiver operating characteristic (ROC) analysis. The Kaplan-Meier method, univariate and multivariate Cox regression analyses were used to analyze the predictors for disease-free survival (DFS) and overall survival (OS). Results: A total of 255 NSCLC patients were enrolled in this study, with 205 stage pIA and 50 stage pT1N1-2M0 NSCLC patients. The independent predictors of DFS in pIA NSCLC patients were neutrophil to lymphocyte ratio (NLR) [P=0.005, hazard ratio (HR) =3.869, 95% confidence interval (CI): 1.499-9.986] and serum carcinoembryonic antigen (CEA) (P=0.007, HR =2.506, 95% CI: 1.281-4.901). The independent predictors of OS in pIA NSCLC patients were systemic inflammatory response index (SIRI) (P=0.03, HR =2.501, 95% CI: 1.110-5.636), CEA (P=0.002, HR =3.691, 95% CI: 1.646-8.280) and serum squamous cell carcinoma antigen (SCCA) (P=0.004, HR =4.323, 95% CI: 1.606-11.640). The NSCLC patients with SIRI >0.981 group and CEA >3.78 ng/mL group were similar to those in pN1 group in 3-year OS rates (89.7%, 94.0% Conclusions: For patients with pIA pure-solid NSCLC, preoperative biomarkers SIRI, NLR, CEA, and SCCA may serve as predictors for postoperative survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.